Apellis has secured a decisive evidence win for Empaveli (pegcetacoplan) in rare renal disease: the New England Journal of Medicine has published Phase 3 VALIANT results in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), showing a 68% reduction in proteinuria at 26 weeks, stabilization of kidney function, and marked clearance of C3 deposits on biopsy. The publication follows the FDA’s July 2025 approval of Empaveli for patients 12 and older to reduce proteinuria in these indications, with a European CHMP opinion expected before year-end. For an estimated 5,000 patients in the U.S. and up to 8,000 in Europe—half of whom may progress to kidney failure within a decade—this represents one of the first approved systemic therapies targeting the complement cascade at C3.
The strategic question is whether a proteinuria-led label, supported by concordant eGFR and histologic signals, is sufficient to reset clinical practice and payer behavior before outcomes data mature and oral competitors arrive. VALIANT’s inclusion of adolescents, adults, and post-transplant patients, and its alignment of functional, biomarker, and tissue endpoints, gives Apellis a comprehensive clinical narrative. Yet the approval hinges on a surrogate, putting the onus on real-world evidence to demonstrate delay of dialysis, transplant, and recurrence after transplant—metrics that drive payer value and nephrologist adoption.
Commercially, Empaveli enters an ultra-rare but high-cost domain where dialysis and transplant avoidance can justify specialty pricing if the case is tight. The twice-weekly subcutaneous regimen implies a services-heavy launch: patient identification through biopsy and complement pathway testing, specialty distribution, and home-infusion support. In the U.S., coverage will likely track the recent playbook from IgA nephropathy, where proteinuria became an accepted surrogate, but prior authorization criteria, center-of-excellence models, and outcomes-based contracting may determine real uptake. Ex-U.S., Sobi’s role and HTA dynamics will hinge on projecting hard renal outcomes from short-term surrogates; expect conditional reimbursement tied to registries and long-term follow-up.
Medical Affairs becomes pivotal. Nephrologists will need clear guidance on who benefits most—native-kidney versus post-transplant cases, complement-genetic or autoantibody-driven disease, and treatment timing relative to disease activity. The histologic data, including high rates of C3 clearance, open a path for pathology-informed treatment decisions, but also demand standardized biopsy practices and centralized reading in routine care. VALIANT’s pediatric inclusion offers a platform for earlier intervention, but it also heightens expectations for longitudinal safety and growth outcomes, expanding the agenda for observational studies and patient-reported endpoints.
The competitive backdrop is intensifying. First-mover advantage at C3 brings brand visibility and clinical familiarity, but the convenience narrative is not yet settled. Oral alternative pathway inhibitors—particularly factor B and factor D agents under development—aim to compress the initiation burden and challenge persistence barriers inherent to frequent infusions. Without head-to-head data, differentiation will pivot to the depth and durability of proteinuria reduction, preservation of eGFR over years, histologic normalization, quality of life, and health-economic outcomes across dialysis and transplant avoidance.
If Empaveli can translate its biomarker triad into credible real-world reductions in progression and transplant recurrence, it could set the template for complement-targeted care in rare glomerulopathies. The next six to twelve months will reveal whether CHMP, early payer agreements, and center-level protocols coalesce fast enough to establish standard-of-care status before oral competitors and longer-term outcomes data redefine the bar.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
